Is Sermorelin Legal in Virginia? Federal Rules, State Law, and How to Get a Prescription

The Short Answer on Virginia Legality

Sermorelin is legal in Virginia. No provision of the Virginia Drug Control Act or the Virginia Board of Pharmacy regulations prohibits its prescription or dispensing. The operative legal constraints are federal, not state-level, and they govern how compounding pharmacies may prepare the drug rather than whether patients may receive it.

A licensed Virginia prescriber may write a sermorelin order, and a properly permitted Virginia compounding pharmacy may fill it, provided both parties follow the 503A or 503B pathways established under the federal Drug Quality and Security Act of 2013 (DQSA, FDA overview).

What Sermorelin Actually Is

Mechanism and Peptide Class

Sermorelin acetate is a synthetic analogue of the first 29 amino acids of endogenous growth-hormone-releasing hormone (GHRH 1-29). It binds GHRH receptors on pituitary somatotrophs, stimulating pulsatile release of growth hormone (GH) rather than supplying exogenous GH directly. This distinction matters legally and clinically: sermorelin is not human growth hormone (HGH), and it is not subject to the heightened restrictions in 21 U.S.C. 333(e) that apply specifically to HGH.

Because GH secretion remains under normal pituitary feedback control, sermorelin avoids the supraphysiologic GH spikes associated with direct GH injection. A 1996 randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=96, men aged 60 to 80) showed sermorelin 0.03 mg/kg/day increased mean serum IGF-1 by approximately 39% over 26 weeks compared to placebo [1].

FDA Approval History

The FDA approved Geref (sermorelin acetate for injection) in 1997 for the treatment of idiopathic growth-hormone deficiency in children. Geref was voluntarily withdrawn from the U.S. Market in 2008 for commercial, not safety, reasons. Because no brand-name sermorelin product is currently marketed, all sermorelin dispensed today is compounded, a point that defines the entire legal framework patients and prescribers must manage (FDA drug databases).

Federal Compounding Law: The Framework That Controls Access

503A Versus 503B: Core Differences

Two pathways govern compounded drug access in the United States. Understanding both is necessary for any Virginia patient or prescriber.

503A pharmacies are traditional state-licensed compounding pharmacies. Under 21 U.S.C. 503A, they may compound a drug without prior FDA approval if: (1) a licensed prescriber issues a valid patient-specific prescription, (2) the drug is not commercially available in identical form, (3) the drug is not on the FDA's "Category 1" list of substances that may not be compounded, and (4) the pharmacy is in good standing with its state board (21 U.S.C. 503A text via FDA).

503B outsourcing facilities are FDA-registered manufacturers that may produce large batches without patient-specific prescriptions, supplying hospitals and clinics. They operate under current Good Manufacturing Practice (cGMP) standards and face more rigorous federal inspection than 503A pharmacies (FDA 503B outsourcing facility list).

Sermorelin's Position on FDA Bulk-Substances Lists

The FDA maintains lists of bulk drug substances it has evaluated for compounding. As of January 2025, sermorelin does not appear on the FDA's Category 1 "do-not-compound" list. It is also not currently on the 503B Bulks List of nominated substances that FDA has affirmatively approved for outsourcing-facility use.

The practical consequence: a 503A pharmacy with a valid patient-specific prescription may compound sermorelin lawfully. A 503B facility cannot legally produce sermorelin in bulk batches until or unless FDA adds it to the 503B Bulks List (FDA bulk-substances evaluation). This is a nuance that affects clinic-supply chains but does not prevent individual patients from obtaining prescriptions.

The "Essentially a Copy" Rule

503A pharmacies must not compound a drug that is "essentially a copy" of a commercially available product. Because no commercial sermorelin product is currently on the U.S. Market, this restriction does not apply to sermorelin today (FDA compounding policy guidance).

Virginia State Law: What the Commonwealth Actually Says

Virginia Drug Control Act and Scheduling

The Virginia Drug Control Act (Va. Code § 54.1-3400 et seq.) adopts the federal DEA scheduling framework and adds some state-specific controlled substances. Sermorelin is not a DEA Schedule I through V substance, and the Virginia Board of Pharmacy has not independently scheduled it (Virginia Board of Pharmacy regulations, 18 VAC 110-20). There is no Virginia analog of a growth-peptide ban.

Virginia Board of Pharmacy Compounding Rules

Virginia compounding pharmacies operate under 18 VAC 110-20 and must hold a current Virginia compounding permit. The Board requires compliance with USP Chapter 797 (sterile compounding) for injectable peptides. Sermorelin is typically prepared as a sterile lyophilized powder for reconstitution with bacteriostatic water, placing it firmly in the USP 797 category (USP 797 overview, NIH/NLM).

A Virginia pharmacy that dispenses compounded sermorelin without a valid state compounding permit and without a patient-specific prescription violates Virginia law independent of federal requirements. Patients should verify that any dispensing pharmacy holds an active Virginia Board of Pharmacy permit, searchable at the Virginia Department of Health Professions (VDHP) license lookup.

Prescribing Authority in Virginia

Virginia-licensed MDs, DOs, nurse practitioners (NPs with collaborative or independent practice authority under Va. Code § 54.1-2957), and physician assistants with prescriptive authority may all write sermorelin prescriptions. No special waiver or DEA-X number is required because sermorelin is not a controlled substance.

The prescriber must establish a valid patient-provider relationship before issuing any prescription. Virginia adopted a telehealth framework under Va. Code § 54.1-3303 that permits this relationship to be established via synchronous audio-visual telemedicine, meaning a Virginia patient can legally receive a sermorelin prescription through a licensed telehealth platform without an in-person visit, provided the clinician conducts a sufficient evaluation (Virginia telehealth statute reference via AAFP telehealth policy).

Clinical Basis: Who Actually Qualifies for Sermorelin

Approved and Off-Label Uses

The original FDA approval covered pediatric idiopathic GH deficiency. After Geref's market withdrawal, all adult use became off-label. Off-label prescribing is legal under federal and Virginia law when a clinician determines it is medically appropriate (FDA off-label use policy).

Current off-label applications include:

• Adult GH deficiency secondary to pituitary pathology
• Age-related decline in GH secretion (somatopause)
• Recovery support in body composition programs supervised by an endocrinologist or sports medicine physician

Diagnostic Workup Before Prescribing

A responsible prescriber will obtain, at minimum:

• Fasting serum IGF-1 (reference range varies by age and sex; the Endocrine Society's 2011 Clinical Practice Guideline on Adult GH Deficiency defines biochemical GHD as a peak GH <3 mcg/L on an GHRH-arginine stimulation test) [2]
• A comprehensive metabolic panel to rule out hepatic or renal contraindications
• Fasting glucose and HbA1c (GH stimulation mildly increases insulin resistance)
• A baseline physical exam or telemedicine-equivalent structured assessment

The Endocrine Society guideline states directly: "We recommend using age- and sex-normalized IGF-1 values as the initial biochemical test to evaluate GH secretion in adults with suspected GHD." [2]

Typical Dosing Protocol

Compounded sermorelin is most commonly prescribed at 200 to 500 mcg subcutaneously, injected nightly before sleep to mimic physiologic GH pulsatility. Treatment courses typically run 3 to 6 months before reassessment of IGF-1. A crossover study (N=40) published in the Journal of Clinical Endocrinology and Metabolism found that 6 months of sermorelin increased mean lean body mass by 1.5 kg and reduced fat mass by 1.2 kg compared to baseline, with no serious adverse events reported [3].

The HealthRX clinical team uses a four-gate decision framework before prescribing sermorelin:

1. Symptom gate. Patient reports at least two of: poor sleep quality, reduced exercise recovery, low libido, increased central adiposity, or cognitive fog.
2. Lab gate. Serum IGF-1 falls below the age-adjusted 25th percentile on a Quest or LabCorp age-sex normative table.
3. Safety gate. No active malignancy, no untreated diabetes (HbA1c <8.5%), no uncontrolled intracranial hypertension.
4. Pharmacy gate. Prescription is routed only to a 503A-permitted pharmacy with current USP 797 accreditation and active Virginia Board of Pharmacy registration.

All four gates must clear before a prescription is issued.

How to Get Sermorelin in Virginia: Step-by-Step

Step 1. Choose a Qualified Prescriber

Select a Virginia-licensed MD, DO, NP, or PA who works in endocrinology, functional medicine, sports medicine, or a telehealth hormone clinic. Verify licensure at the VDHP license lookup (dhp.virginia.gov). Telehealth platforms licensed to operate in Virginia are a legal and practical option.

Step 2. Complete a Medical Evaluation

Expect a detailed history, symptom questionnaire, and blood work. At minimum, labs should include IGF-1, comprehensive metabolic panel, fasting glucose, HbA1c, and a standard hormone panel. Some prescribers also order a GHRH-arginine stimulation test or an insulin tolerance test when GH deficiency is suspected rather than confirmed by IGF-1 alone (Endocrine Society GHD guideline, endocrine.org).

Step 3. Receive a Patient-Specific Prescription

If the clinical picture supports sermorelin, the prescriber issues a written prescription specifying the compound, dose, concentration, volume per dose, route of administration, and quantity dispensed. This is the legal document that authorizes a 503A pharmacy to compound and ship the drug.

Step 4. Verify the Pharmacy's Credentials

Before filling, confirm the pharmacy holds:

• An active Virginia Board of Pharmacy compounding permit (or a valid out-of-state permit for interstate dispensing, which requires the pharmacy to hold a Virginia non-resident pharmacy permit)
• USP 797 compliance documentation for sterile preparations
• PCAB accreditation is optional but adds quality assurance

The FDA maintains a searchable list of pharmacies that have received warning letters or import alerts; checking it takes under two minutes (FDA warning letters database).

Step 5. Injection Training and Storage

Compounded sermorelin arrives as a lyophilized powder. The patient reconstitutes it with bacteriostatic water and stores the solution at 2 to 8 degrees Celsius (refrigerator temperature). Proper subcutaneous injection technique should be demonstrated or reviewed by the dispensing pharmacist or prescribing clinician before the first dose.

Step 6. Follow-Up Labs

The prescriber should recheck IGF-1 at 8 to 12 weeks into therapy and again at 6 months. Side effects to monitor include injection-site reactions (reported in approximately 17% of subjects in early clinical trials), transient flushing, and mild headache [1]. If IGF-1 rises above the age-sex-adjusted upper limit of normal, the dose should be reduced.

Risks of Obtaining Sermorelin Outside Legal Channels

Purchasing sermorelin from international online vendors or gray-market research-chemical suppliers is a federal felony risk in addition to a health risk. Product sold without a prescription bypasses the 503A/503B quality controls, meaning sterility, potency, and peptide integrity are unverified. The FDA has issued multiple warning letters to peptide vendors selling research-grade compounds for human use (FDA warning letters for unapproved peptides). Virginia law independently prohibits dispensing prescription drugs without a valid prescription under Va. Code § 54.1-3466. The penalties include felony charges for the seller and potential civil liability.

Sermorelin Versus BPC-157, TB-500, and Other Peptides: A Legal Contrast

Patients researching sermorelin often encounter other peptides. The legal picture differs substantially:

• BPC-157. Nominated for the 503B Bulks List but currently placed on FDA's Category 2 list of substances under further evaluation. The FDA issued a policy notice in 2022 stating it does not consider BPC-157 to be a lawfully marketed drug for compounding purposes, creating meaningful legal risk (FDA bulk substances 503B evaluation).
• TB-500 (Thymosin beta-4). No FDA approval, no approved IND for human therapeutic use, and not on any positive compounding list. High legal risk under current FDA enforcement posture.
• Sermorelin. Prior FDA approval (Geref), historical compounding precedent, and no current negative listing make it the lowest-risk peptide for compounded prescription use in Virginia.

A 2023 analysis of FDA enforcement actions against compounding pharmacies found that BPC-157 and TB-500 accounted for 38% of peptide-related warning letters, while sermorelin did not appear on the list (NIH PMC review of compounding enforcement trends).

Telehealth Access for Virginia Residents

Virginia's telehealth statute (Va. Code § 54.1-3303) and the State Board of Medicine regulations (18 VAC 85-20) permit synchronous audio-visual consultations as the basis for a valid patient-provider relationship. A prescriber may not issue a prescription based solely on an online questionnaire without a real-time audio-visual interaction, but a proper telehealth visit fully satisfies the relationship requirement.

The Drug Enforcement Administration's 2023 Special Registration for telemedicine prescribing covers controlled substances. Sermorelin is not a controlled substance, so the DEA telemedicine rules do not add any additional hurdle (DEA telemedicine rules via FDA/DEA policy page). A Virginia patient can complete an intake form, attend a live video visit with a licensed clinician, receive blood-work orders, review results in a follow-up visit, and obtain a sermorelin prescription entirely via telehealth.

Summary of the Legal Checkpoints

| Checkpoint | Requirement | Governing Authority | |---|---|---| | Prescription required | Yes, patient-specific | 21 U.S.C. 503A; Va. Code § 54.1-3466 | | Prescriber must be VA-licensed | Yes | Virginia Board of Medicine | | Pharmacy must hold VA permit | Yes (or non-resident permit) | Virginia Board of Pharmacy | | Sterile compounding standard | USP 797 compliance | Virginia 18 VAC 110-20 | | Federal scheduling | Not scheduled (DEA I-V) | DEA / 21 U.S.C. 812 | | FDA positive compounding list | Not required for 503A | 21 U.S.C. 503A | | FDA negative (do-not-compound) list | Not listed as of 2025 | FDA bulk substances database |

Any prescriber, pharmacy, or telehealth platform operating under all seven checkpoints is acting within the law.